Introduction {#s1}
============

An adaequate supply of oxygen is mandatory for aerobic life. To cope with an inadequate O~2~ supply, commonly termed hypoxia, mammals have developed response mechanisms which are crucial for their survival.

To achieve responsiveness toward hypoxia on the molecular level, cells integrate a complex biochemical system involving short-term reactions/modifications with no changes in gene expression and a long-term programme including changes in gene expression. Both processes can be interlinked; in particular, when the short-term response includes changes in the activity of enzymes which initiate a series of posttranslational signaling events that often regulate the activity of transcription factors and thus gene expression. On the level of gene expression the response to hypoxia is crucially dependent on the α-subunits of hypoxia-inducible transcription factors (HIFα) (Semenza, [@B135]; Kaelin, [@B75]; Masson and Ratcliffe, [@B105]).

As such, HIF α-subunit proteins contribute to proper embryonic development and to the pathology of many diseases associated with hypoxia like anemia, myocardial infarction, thrombosis, atherosclerosis, diabetes mellitus, or cancer (Semenza, [@B135]; Kaelin, [@B75]; Masson and Ratcliffe, [@B105]).

To achieve adaequate function, HIFα levels, subcellular distribution and activity need to be tightly regulated. Although regulation at the transcriptional and translational level was shown to play a role, posttranslational stabilization of HIFα proteins in response to hypoxia appears to be of major importance (Wenger, [@B157]; Gross et al., [@B54]; Gorlach, [@B48]; Kietzmann, [@B79]).

Interestingly, the HIFα proteins are not only regulated by hypoxia, but also in response to various stresses, growth and coagulation factors, hormones, or cytokines under normoxic conditions (reviewed by Dimova et al., [@B32]). These "normoxic" HIFα stimuli often use different protein kinase regulated pathways for signal transduction indicating an important role of different kinases in HIFα regulation. Indeed, different kinases have been identified to regulate HIFα in a direct or indirect fashion (Figure [1](#F1){ref-type="fig"}). This review will primarily discuss the role of the kinases using HIFα proteins as a direct substrate and the impact of these modifications on HIFα stabilization, nuclear translocation, and transactivation.

![**Scheme of kinases involved in regulating HIF-1α either direcly or indirectly**. AMPK, AMP-activated kinase; ATM, ataxia and teleangiectasia mutated; CK1, casein kinase1; CDK1, cyclin-dependent kinase-1; ERK; extracellular regulated kinase; GSK3β, glycogen synthase kinase-3β; PKA, protein kinase A; PKB/Akt, protein kinase B or Akt kinase; p38, p38 mitogen activated protein kinase; Plk3, polo-like kinase-3.](fcell-04-00011-g0001){#F1}

Hypoxia-inducible transcription factors: α- and β-subunits {#s2}
==========================================================

Three O~2~-sensitive HIFα proteins (HIF-1α, HIF-2α -also known as EPAS (Tian et al., [@B147]), HLF (Ema et al., [@B37]), HRF (Flamme et al., [@B40]), or MOP2 (Hogenesch et al., [@B62])---and HIF-3α) are known today. Together with HIF β-subunits, primarily represented by the stable nuclear and ubiquitously found ARNT (arylhydrocarbon receptor-nuclear translocator) protein, they form heterodimeric transcription factors binding to hypoxia response elements (HRE) with the core DNA sequence 5′-RCGTG-3′ (Wenger et al., [@B158]).

The best studied HIFα isoforms are HIF-1α and HIF-2α which share a number of structural and functional similarities but also show some differences with respect to cell type expression pattern, embryonic deletion phenotypes, target genes, and effects during carcinogenesis (Hu et al., [@B63]; Scortegagna et al., [@B134]; Sowter et al., [@B142]). Not much is known about HIF-3α from which several splice variants exist in humans (Pasanen et al., [@B121]) and where some variants as well as a mouse splice variant termed inhibitory PAS protein (IPAS) appear to act as negative regulators of the hypoxic response (Makino et al., [@B101]; Heikkila et al., [@B58]) while others appear to act as an oxygen-regulated transcription activator (for review see Duan, [@B34]).

Like the ARNT proteins, the HIF α-proteins belong to the basic helix-loop-helix (bHLH) PAS (Per-ARNT-Sim) protein family (Wang et al., [@B153]); HIF-1α and HIF-2α show the highest degree of sequence identity in the bHLH (\~85%), PAS-A (\~68%), and PAS-B (\~73%) domains. Both contain also two conserved nuclear localization sequences (NLS) responsible for translocation to the nucleus; they are localized in the N-terminus (aa 17--33 in HIF-1α; aa 1--50 in HIF-2α) and in the C-terminus (aa 718--721 in HIF-1α; aa 689--870 in HIF-2α) (Kallio et al., [@B76]). Except for the full length HIF-3α which does not contain a C-terminal transactivation domain but a unique LZIP (leucine zipper) C-terminal domain (Hara et al., [@B55]; Kietzmann et al., [@B81]), HIF α-subunits contain also a N-terminal transactivation domain (N-TAD) and a C-terminal transactivation domain (C-TAD). An oxygen-dependent degradation domain (ODDD, aa 401--603 in HIF-1α; aa 517--682 in HIF-2α) is overlapping the N-TAD and is important for the oxygen-dependent regulation of all vertebrate HIFα proteins (Huang et al., [@B64]; Duan, [@B34]). The residues between the N-TAD and C-TAD constitute an inhibitory domain (ID) (Jiang et al., [@B72]) (Figure [2](#F2){ref-type="fig"}).

![**Kinases and amino acid residues in HIF-1α involved in regulation of HIF-1α stability**. Scheme of HIF-1α and its domain organization with specific amino acid residues which can be phosphorylated; all have been shown to contribute to the regulation of HIF-1α protein stability. HIF-1α is phosphorylated on specific residues (T498, S502, S505, T506, and S510 or S551, T555, and S589) by GSK3β; Plk3 can phosphorylate S576 and S657; ATM can phosphorylate S696 and CDK1 can phosphorylate S668. ATM, ataxia and teleangiectasia mutated; CDK1, cyclin-dependent kinase-1; GSK3β, glycogen synthase kinase-3b; Plk3, polo-like kinase 3; bHLH, basic helix loop helix domain; NLS, nuclear localization sequence; PAS, Per-ARNT-Sim domain; N-TAD, N-terminal transactivation domain; ID, inhibitory domain; C-TAD, C-terminal transactivation domain; numbers indicate the amino acid residue range of the respective domain.](fcell-04-00011-g0002){#F2}

Hypoxia-inducible regulation of α-subunits {#s3}
==========================================

The levels of the HIF α-subunits increase exponentially with declining O~2~ concentration as a result of reduced hydroxylation, ubiquitylation and proteasomal degradation (Semenza, [@B135]; Kaelin, [@B75]; Masson and Ratcliffe, [@B105]). To date, four HIF specific prolyl 4-hydroxylase domain containing enzymes (PHDs) have been identified from which PHD2 appears to be of major importance for HIFα degradation (Berra et al., [@B12]). All HIF hydroxylases belong to a family of dioxygenases which depend on the presence of O~2~ for their action. Thus, in the presence of O~2~, i.e., normoxia, PHDs are able to hydroxylate crucial proline residues in the HIFα ODDDs (P402/P564 in HIF-1α; P405/P531 in HIF-2α; P492 in HIF-3α). This event recruits the von Hippel-Lindau tumor suppressor protein (pVHL) which together with Elongin C, Elongin B, RBX1, Cullin 2, and an E2 ubiquitin-conjugating enzyme forms an ubiquitin E3 ligase complex. As a consequence, HIFα proteins become ubiquitylated and degraded by the proteosome (Semenza, [@B135]; Kaelin, [@B75]; Masson and Ratcliffe, [@B105]).

Another hydroxylase called factor-inhibiting HIF (FIH-1) hydroxylates an asparagine in the C-TADs of HIF-1α and HIF-2α (N803 in HIF-1α and N847 in HIF-2α) with the result that the interaction of the HIFα proteins with the co-activators CBP/p300 is inhibited (Mahon et al., [@B100]; Hewitson et al., [@B59]; Lando et al., [@B89]). Thus, a limited O~2~ supply decreases the activities of HIF hydroxylases and allows HIFα stabilization, followed by nuclear translocation, dimerization, and transactivation (for review see Kaelin, [@B74]).

Regulation of HIF α-subunits by phosphorylation {#s4}
===============================================

Phosphorylation is a crucial posttranslational modification which regulates the activity and stability of various proteins including transcription factors. However, the extent to which transcription factors including HIFα proteins are phosphorylated may vary according to the signal, cell-type, or tissue. Thus, it is plausible that a modulation of HIFα action due to phosphorylation may be a cell type specific event which could be explained by different layers of regulations where kinases are affected depending on the cellular context.

The first evidence indicating that phosphorylation plays a role in HIFα regulation came from electrophoretic mobility shift assay experiments where addition of calf intestinal alkaline phosphatase to hypoxic nuclear extracts led to a loss of HIF-1 DNA-binding activity (Wang et al., [@B154]). In the meantime a panel of protein kinases was reported to affect HIFα regulation, mainly HIF-1α, indirectly or directly (for review see Dimova et al., [@B32]). Thereby it appeared that direct phosphorylation of HIFα has an immediate impact on HIFα stability, nuclear localization, transactivity, and protein-protein interactions.

Phosphorylation of HIFα proteins: role for subunit stabilization
----------------------------------------------------------------

A number of findings indicated that the PI3K/PKB(Akt) pathway can induce HIFα, transcription, stabilization (Mazure et al., [@B106]; Zhong et al., [@B162]; Zundel et al., [@B163]; Hirota and Semenza, [@B60]), translation (Koritzinsky et al., [@B85]), and coactivator recruitment (Kallio et al., [@B76]). So far, no evidence has been presented showing that HIFα proteins are directly phosphorylated by PKB(Akt); rather its action is indirect involving other PKB/Akt targets. Although a number of PKB/Akt targets are known, so far only the human homolog of mouse double minute-2 (HDM2) (Bardos et al., [@B8]; Skinner et al., [@B139]), mammalian target of rapamycin (mTOR) (Treins et al., [@B151]), and glycogen synthase kinase-3 (GSK3) (Flügel et al., [@B42], [@B41]) were shown to affect HIF-1α levels with most evidence indicating that only GSK3 acts directly on HIF-1α.

Although the name GSK3 implies that this is a specific kinase acting only on glycogen synthase, it is rather pleiotropic with a number of substrates through which GSK3 may affect various signaling pathways often associated with hypoxia like developmental processes, stem cell renewal, cell proliferation, and apoptosis (reviewed in Cohen and Frame, [@B21]; Grimes and Jope, [@B53]; Force and Woodgett, [@B43]).

Mammals possess two GSK3 isoforms, GSK3α (51 kDa) and GSK3β (47 kDa) which are structurally similar, but not entirely functionally overlapping (reviewed in Force and Woodgett, [@B43]). This became evident from the different phenotypes of GSK3 knockout mice. GSK3β^−∕−^ mice are embryonically lethal and die around day 16 because of hepatic apoptosis and a cardiac pattern defect (Hoeflich et al., [@B61]; Kerkela et al., [@B78]). By contrast, GSK3α^−∕−^ mice are viable, and fertile (MacAulay et al., [@B99]). Interestingly, it exists also a minor spliced GSK3β variant called GSK3β2 that contains a 13-amino acid residue insert within the kinase domain. This isoform was shown to be neuron-specific and has reduced kinase activity toward the microtubule-associated protein, tau, compared to GSK3β (Mukai et al., [@B114]; Saeki et al., [@B128]).

GSK3 is a target of the PKB/Akt pathway and it is unusual that its protein kinase activity tends to be high in resting cells. Furthermore, its inhibition is mediated by various stimuli, such as growth factors, cytokines, and hormones. PKB/Akt can phosphorylate both GSK3 isoforms (S21 of GSK3α and S9 of GSK3β), leading to an inhibition of GSK3 activity (Cross et al., [@B26]). Several other kinases are also able to phosphorylate these serine residues like ERK1/2, a downstream kinase of the MAPK pathway (Brady et al., [@B14]), p70 ribosomal S6 kinase-1 (Armstrong et al., [@B4]), cAMP-dependent protein kinase A (PKA) (Li et al., [@B93]), and PKC (Ballou et al., [@B7]).

Findings showing that inhibition of GSK3, siRNA-mediated depletion of GSK3β and absence of GSK3β in MEFs induced HIF-1α protein levels (Schnitzer et al., [@B133]; Flügel et al., [@B42], [@B41]) were in line with the notion that GSK3 can phosphorylate at least HIF-1α. Indeed, GSK3β was found to directly phosphorylate HIF-1α in the ODDD and N-TAD (Sodhi et al., [@B140]; Flügel et al., [@B42], [@B41]; Cassavaugh et al., [@B18]). The residues phosphorylated in HIF-1α by GSK3β were reported to be S551, T555, and S589 in one study (Flügel et al., [@B42]) whereas another study showed involvement of T498, S502, S505, T506, and S510 (Cassavaugh et al., [@B18]) (Figure [2](#F2){ref-type="fig"}). The difference between studies may have resulted from different oxygen concentrations (8% O~2~ compared to 2% O~2~) and the different cell types (HepG2 compared to SK-OV-3) used. Despite the different phosphorylation sites, both studies show that regulation of HIF-1α by GSK3β is independent of O~2~, hydroxylation, and VHL-mediated proteasomal degradation (Flügel et al., [@B42], [@B41]; Cassavaugh et al., [@B18]). Thereby, phosphorylation of HIF-1α by GSK3β recruits the F-box and WD protein Fbw7 (also known as hCdc4 in yeast, hSel10 in *Caenorhabditis elegans*, or Ago in Drosophila) as the substrate-recognition component of a multi-subunit E3 ubiquitin ligase and forms together with SKP1 (S-phase kinase-associated protein 1), CUL1 (cullin 1), and RBX1 (RING box 1, also called ROC1 or HRT1) the so called SCF complex which then contributes to HIF-1α degradation (Cassavaugh et al., [@B18]; Flügel et al., [@B41]).

Similar to pVHL, Fbw7 is also a tumor suppressor; 6% from 1500 investigated human tumors showed mutations in the Fbw7 coding region. Strikingly, nearly half (43%) of these were missense mutations within the WD40 domain (Arg465 and Arg479), shared by all three alternatively spliced Fbw7 isoforms. In line, all three Fbw7 isoforms could target HIF-1α for proteasomal degradation and loss of the Fbw7 WD domain abolished GSK3β initiated HIF-1α degradation (Flügel et al., [@B41]).

Together, the findings showing that two different E3 substrate recognition proteins which both are tumor suppressors can contribute to HIFα degradation indicates the importance of the highly dynamic HIF system for carcinogenesis.

Ubiquitylation of proteins is reversible and the reversion is mediated by a family of deubiquitylating enzymes (DUBs). About 100 DUBs encoded by the human genome are supposed to counteract the action of around 600 E3 ligases (Nijman et al., [@B119]; Scheel and Hofmann, [@B132]). DUBs can be divided into five groups: ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs), Josephins, and JAMMs. The USP, UCH, OUT, and Josephins are papain-like cysteine proteases, whereas the JAMM members are zinc metalloproteases (reviewed in Love et al., [@B98]).

Based on this, it appears plausible that the normoxia and pVHL-mediated ubiquitylation as well as the GSK3β and Fbw7-mediated ubiquitylation can be opposed by DUBs. Indeed, two VHL-interacting deubiquitylating enzymes, VDU1 (USP33) and VDU2 (USP20) were identified (Li et al., [@B95],[@B97]). However, by using *in vitro* pull down assays with GST-HIF-1α (amino acid 530--826) and co-immunoprecipitation experiments in COS-7 cells it was shown that only VDU2 but not VDU1 could interact with HIF-1α (Li et al., [@B96]). In addition, it was shown that VDU2 but not VDU1 can deubiquitylate HIF-1α and increase it\'s half-life (Li et al., [@B96]).

Experiments with GSK3β and Fbw7-deficient cells revealed that the GSK3β and Fbw7-dependent HIF-1α degradation can be antagonized by the ubiquitin specific protease 28 (USP28) (Flügel et al., [@B41]). In contrast to VDU2 which directly interacts with HIF-1α, USP28 forms a ternary complex with HIF-1α via its association with HIF-1α bound Fbw7 (Flügel et al., [@B41]).

Together, degradation of HIF-1α by the GSK3/Fbw7/USP28 system appears to be an additional mode to regulate HIF-1α function in response to various physiologic and non-physiologic signals affecting cell division, cell growth, differentiation, and apoptosis independent of the O~2~ tension.

While GSK3 provides a metabolic link to cell growth and differentiation, p38 MAP kinases link different stress stimuli, such as ultraviolet irradiation, heat shock, and osmotic shock with cell differentiation, apoptosis, and autophagy (Olson and Hallahan, [@B120]; Raman et al., [@B122]; Tormos et al., [@B149]; Sabio and Davis, [@B127]). Indeed, p38 was supposed to regulate HIF-1α stability during ischemic stress and in line, the p38 inhibitors SKF86002 and SB203580 decreased HIF-1 dependent gene expression (Sodhi et al., [@B140]). Further, treatment of the MiaPaca2 pancreatic cancer cell line with the p38 inhibitor SB203580 caused an increase in VHL-HIF-1α binding (Kwon et al., [@B87]) suggesting that p38 contributes to HIF-1α stabilization, though no half-life measurements were performed. Two members of the p38 MAPK family, p38α and p38γ, were then shown to possess the ability to phosphorylate HIF-1α (Sodhi et al., [@B141]). Altogether, this implies that p38 can contribute to HIF-1α stabilization, the phosphorylation by p38 occurred in the inhibitory domain (aa 576--785) (Sodhi et al., [@B140]) which has not yet been shown to be involved in VHL-dependent degradation. Moreover, the exact localization of the eight serine residues which could serve as putative p38 phosphorylation sites in the HIF-1α inhibitory domain as well as their contribution to HIFα degradation remains still to be determined (Figure [2](#F2){ref-type="fig"}).

Another kinase linking HIFα function with regulation of cell division is cyclin-dependent kinase 1 (CDK1). Although about 20 CDKs known to date can contribute to cell cycle control, CDK1 was found to be the only one essential for the cell cycle in all eukaryotic cells (Malumbres et al., [@B104]). CDK1 belongs to a highly conserved family of heterodimeric serine/threonine kinases which require a regulatory cyclin subunit for their activity. As such, the CDK1-cyclin B complex constitutes a serine/threonine protein kinase composed of the catalytic subunit CDK1 and its positive regulatory subunit cyclin B (B1 isoform) (Malumbres et al., [@B104]).

Activation of CDK1 promotes entry into the M phase of the cell cycle. This is achieved in the late G2 phase by phosphorylation mediated by the CDK activating kinase (CAK) phosphorylating T161 in its kinase-activation loop (Russo et al., [@B126]) as well as Cdc25C phosphatase mediated dephosphorylation of T14 and Y15 within CDK1. The inactive state of CDK1 throughout the S and G2 phases of the cell cycle is achieved by phosphorylation at two negative regulatory sites, T14 and Y15, by the CDK1 inhibitory protein kinases, Myt1 and Wee1 respectively (Watanabe et al., [@B156]) for review see (Malumbres, [@B102], [@B103]).

A recent report showed that siRNA-mediated knockdown or Ro-3306-mediated inhibition of CDK1 reduced HIF-1α half-life whereas overexpression of CDK1 enhanced HIF-1α levels. *In vitro* kinase assays revealed that S668 in HIF-1α is the CDK1 target site (Figure [2](#F2){ref-type="fig"}). Accordingly, a construct of HIF-1α with a phospho-site mimicking mutation (S668E) was more stable under both normoxia and hypoxia. Moreover, phosphorylation of HIF-1α at S668 lead to an expression of HIF-1 target genes and promoted tumor angiogenesis, proliferation, and tumor growth (Warfel et al., [@B155]). Together, these findings underlie the importance of HIF-1α for the M-phase of the cell cycle since it can be stabilized by CDK1-mediated phosphorylation already under normoxia.

Genotoxic stress represents a burden under which cell cycle progression and cell cycle checkpoints need to be tightly controlled. A kinase participating in the response to genotoxic stresses is Polo-like kinase 3 (Plk3) (Barr et al., [@B9]). Plk3 is a member of a family consisting of four proteins (Plk1, Plk2, Plk3, and Plk4) not only involved in the stress response, but also strongly involved in tumorigenesis with an abnormal expression found in multiple tumors (Archambault and Glover, [@B3]; Degenhardt and Lampkin, [@B28]). The role of Plk3 in the development of tumors remains controversial. While one study showed a non-tumorigenic phenotype in Plk3 deficient mice (Myer et al., [@B115]), another study reported that mice deficient in Plk3 develop highly vascularized tumors in multiple organs suggesting a tumor-suppressing activity in particular via HIF driven angiogenesis (Yang et al., [@B161]). The latter finding is in line with the finding that Plk3 can regulate HIF-1α stability (Xu et al., [@B160]). Plk3 immunoprecipitation and pulldown analyses revealed interaction between HIF-1α and Plk3 which was able to phosphorylate S576 and S657 of HIF-1α (Xu et al., [@B160]) (Figure [2](#F2){ref-type="fig"}). Further, Plk3^−^/^−^ murine embryonic fibroblasts contained increased HIF-1α levels. In line with that, half-life measurements demonstrated that the half-life of wild-type HIF-1α was \< 10 min, whereas the half-lives of the HIF-1α-S576A, HIF-1α-S657A, and HIF-1α-S576A/S657A mutants were about 37, 49, and 51 min, respectively (Xu et al., [@B160]). Together, these studies indicate that Plk3-mediated phosphorylation destabilizes HIF-1α.

In contrast to the above mentioned kinases, the knowledge about the involvement of the Jun N-terminal kinases (c-JNK) in regulating HIF-1α is quite limited and inconsistent. One study reported that c-JNK contributes to the activation of HIF-1α (Comerford et al., [@B22]) whereas other studies showed that HIF-1α is not phosphorylated by c-JNK (Richard et al., [@B123]; Sodhi et al., [@B140]).

### Links between hypoxia and kinases in the regulation of HIFα stabilization

In addition to hormones or growth factors, hypoxia may also have an impact on the activity of certain kinases and thus activation of the hypoxia signal chain and a kinase pathway at the same time may lead to interference at the level of HIFα.

It has been shown that hypoxia is capable to induce GSK3β phosphorylation and thus its inactivation in different cell types such as PC-12 cells (Beitner-Johnson et al., [@B11]), HT1080 cells (Chen et al., [@B19]), and HepG2 cells (Mottet et al., [@B112]; Flügel et al., [@B42]) as well as *in vivo* (Roh et al., [@B125]). Further, early/acute hypoxia also enhanced PI3K/Akt activity, inhibited GSK3, and increased HIF-1α protein levels whereas prolonged/chronic hypoxia increased GSK3β activity which led to decreased HIF-1α protein levels in HepG2 cells (Mottet et al., [@B112]; Flügel et al., [@B42]). This indicates that hypoxia can also be a signal for the PI3K/Akt/GSK3 pathway and depending on the duration of hypoxia it is possible to induce a biphasic HIF-1α response. This would imply that GSK3β inhibition could reverse the negative effect of prolonged hypoxia on HIF-1α accumulation; however, these effects may be cell type specific since the hypoxia effects on GSK3β phosphorylation were not observed in other cell types including some different breast cancer cell lines (Blancher et al., [@B13]), PC-3 prostate cancer cells (Zhong et al., [@B162]), and 3T3 cells (Laughner et al., [@B90]).

GSK3 appears not to be the only kinase which may regulate HIFα stability by phosphorylation under normoxia and hypoxia. Recently it was found that the protein kinase ataxia-telangiectasia mutated (ATM) may be involved in the hypoxia-dependent modulation of HIF-1α function. Although ATM is best known for its role as an upstream activator of the DNA damage response due to DNA double-strand breaks (DSBs) (Shiloh and Ziv, [@B137]), it was described that ATM-deficient cells failed to accumulate HIF-1α under hypoxic conditions. In addition, ATM activity---but not protein---was found to be increased by about two-fold when NHFB cells were exposed to 0.2% oxygen; an increase in activity similar to that seen after ionizing irradiation. ATM was also able to phosphorylate HIF-1α at S696 in the ID and a HIF-1α S696A mutant was found to be less stable than wild-type HIF-1α under hypoxic conditions suggesting that S696 phosphorylation stabilizes HIF-1α (Cam et al., [@B17]) (Figure [2](#F2){ref-type="fig"}). However, not only stability but also activity of the HIF-1α S696A mutant was reduced with the consequence of reduced DNA-damage-inducible transcript 4 (DDIT4; also known as Dig2, HIF-1-responsive RTP801, REDD-1) expression (Shoshani et al., [@B138]). These features integrate the ATM DNA damage response pathway with the hypoxia signaling pathway.

In addition to hypoxia, reactive oxygen species (ROS) are also an important trigger of the DNA damage response and have been shown to be involved in the regulation of HIFα levels (Kietzmann and Gorlach, [@B82]; Gorlach and Kietzmann, [@B51]; Kietzmann, [@B80]). Although their major effects on HIFα stabilization are exerted via regulation of the proline hydroxylation- and VHL-dependent degradation pathway (Kietzmann and Gorlach, [@B82]; Gorlach and Kietzmann, [@B51]), also the PI3K/Akt and ERK1/2 pathway contributed to the ROS mediated HIFα regulation (Gorlach et al., [@B50], [@B49]; Diebold et al., [@B31]). Recent studies in the roundworm *C. elegans* indicated that another kinase, namely AMP-activated protein kinase (AMPK) couples ROS and HIF-1α regulation in a direct manner. AMPK is a key sensor of the cellular energy status (Hardie et al., [@B56]) and considered to act downstream of reduced mitochondrial respiration. In their studies the authors demonstrated that mutations in the AMPK ortholog of *C. elegans* led to increased levels of HIF-1α indicating that AMPK is required for reducing HIF-1α. Further analyses revealed that AMPK regulates HIF-1α post-transcriptionally and by combining *in vitro* kinase assays with LC-MS analyses it was shown that AMPK phosphorylates S419 in *C. elegans* HIF-1α (Hwang et al., [@B68]) (Figure [2](#F2){ref-type="fig"}). Although, these data raise the possibility that AMPK down-regulates HIF-1α via direct phosphorylation, that study did not address to which extent this phosphorylation involves or requires VHL.

Although the *C. elegans* study also left open whether the direct regulation of HIFα is conserved among other species, it is known from studies with cancer cells that ROS-dependent HIF-1α activation requires AMPK (Jung et al., [@B73]). Interestingly and opposite to the regulation of HIF-1α by AMPK in *C. elegans* a recent study showed a link between AMPK function and HIF-1α regulation in the human hepatic cancer cell line Hep3B (Irigoyen et al., [@B71]; Chen et al., [@B20]). In these cells, the link between AMPK and HIF-1α appeared to be rather indirect involving histone deacetylase 5 (HDAC5) activity which can be phosphorylated by AMPK at S259 and S498. Since this phosphorylation of HDAC5 by AMPK promotes its shuttling from the nucleus to the cytosol (McKinsey et al., [@B107]) the authors examined whether cytosolic HDAC5 activity is involved in HIF-1α stabilization. They found that activation of AMPK by AICAR enhanced cytosolic presence of HDAC5 and levels of HIF-1α whereas the AMPK inhibitor compound C blocked HDAC5 nuclear export and HIF-1α accumulation (Irigoyen et al., [@B71]; Chen et al., [@B20]). Compound C, has also been shown to prevent hypoxia-dependent HIF-1α activation in DU145 cells (Lee et al., [@B92]; Hwang et al., [@B69]); however, this could be an independent effect since the inhibition of HIF-1α by compound C was also seen in AMPK^−∕−^ cells (Emerling et al., [@B38]). Together, it appears that AMPK can be involved in regulation of HIF-1α in a direct and indirect manner where the extent may be also depending on the species.

Altogether, these findings indicate that the HIFα system displays an enormous plasticity since its protein stabilization can be induced by hydroxylation and phosphorylation events either alone or in combination.

Regulation of HIF α-subunit nuclear localization and transactivity by phosphorylation
-------------------------------------------------------------------------------------

Activation of multiple oncogenic pathways including growth factor signaling coupled with enhanced MAPK signaling is a common event in tumors (Raman et al., [@B122]). From the conventional MAP kinases the extracellular regulated kinases, ERK1 and ERK2 (p44/p42), c-Jun NH2-terminal kinase (JNK1/2/3), p38 MAPK (p38α/β/γ/δ) are known to be of importance for regulating cellular processes like proliferation, differentiation, development, stress responses, and apoptosis (Morrison and Davis, [@B111]; Olson and Hallahan, [@B120]; Coulombe and Meloche, [@B25]; Raman et al., [@B122]; Rincon and Davis, [@B124]; Gaestel, [@B46]; Serviddio et al., [@B136]; Tormos et al., [@B149]). Therefore, up-regulation of HIFα activity by MAPK signaling may play an essential role during tumor growth and metastasis.

To be able to act as transcription factor, stabilized HIFα proteins need to be translocated to the nucleus. This nuclear translocation was shown to be independent of ARNT and to be a dynamic process where nuclear import is commonly counterbalanced by nuclear export. Thus, the degree of nuclear HIFα accumulation depends on the relative nuclear import and export rates. In the case of HIFα, nuclear translocation was shown to involve its N-terminal and C-terminal NLS, respectively, as well as its interaction with importin 4 and 7 (Depping et al., [@B29]). The nuclear presence was then further shown to be regulated by ERK1 (p44)---and ERK2 (p42)-dependent phosphorylation. Thereby, mass spectroscopy with *in vitro* phosphorylated recombinant HIF-1α revealed that HIF-1α S641 and S643 (within the ID) served as p42/p44 MAPK targets (Mylonis et al., [@B117]; Triantafyllou et al., [@B152]) (Figure [3](#F3){ref-type="fig"}). Intriguingly, inhibition of these phosphorylation sites impaired HIF-1α nuclear accumulation and transcriptional activity by favoring nuclear export (Mylonis et al., [@B117]; Triantafyllou et al., [@B152]). This implies that ERK1/2 regulates rather the ability of HIFα to exit the nucleus rather than the import. Indeed, an atypical but CRM1 (exportin 1 or chromosome region maintenance)-dependent nuclear export signal (NES) (within aa 616--658 in HIF-1α) (Mylonis et al., [@B116]) was found to be phosphorylation-sensitive. Phosphorylation of S641 and S643 within the NES by ERK1/2 inhibited interaction between HIF-1α and the exporting CRM1 and facilitated nuclear accumulation.

![**Kinases involved in nuclear accumulation of HIF-1α**. Scheme of HIF-1α and its domain organization with specific amino acid residues phosphorylation of which affects nuclear translocation. ERK2, extracellular regulated kinase2; bHLH, basic helix loop helix domain; NLS, nuclear localization sequence; PAS, Per-ARNT-Sim domain; N-TAD, N-terminal transactivation domain; ID, inhibitory domain; C-TAD, C-terminal transactivation domain; numbers indicate the amino acid residue range of the respective domain.](fcell-04-00011-g0003){#F3}

In line with the nuclear accumulation are findings reporting that enhanced transcriptional activity of both HIF-1α and HIF-2α can be observed after direct phosphorylation of the HIFα isoforms by ERK1/2 *in vitro* and *in vivo* (Richard et al., [@B123]; Conrad et al., [@B24]; Minet et al., [@B108]; Sang et al., [@B130]; Mylonis et al., [@B116]). In line, the MEK1 inhibitor PD98059 and MKK inhibitor U0126 decreased HIF-target gene expression (Hur et al., [@B67]; Sodhi et al., [@B140]; Comerford et al., [@B22]; Dimova et al., [@B33]; Kaluz et al., [@B77]).

While the C-TAD of HIF-1α and HIF-2α is important for recruitment of the coactivator CBP/p300, phosphorylation sites within the C-TAD (Minet et al., [@B108]; Sodhi et al., [@B140]; Lee et al., [@B91]) and within the ID (Sodhi et al., [@B140]; Lee et al., [@B91]; Sang et al., [@B130]) of HIFα may also contribute to induction of transactivity. Indeed, the first functionally relevant phosphorylation sites were reported to be T796 in HIF-1α and T844 in HIF-2α (Gradin et al., [@B52]). Although the kinases phosphorylating these sites were not defined, phosphorylation of these residues increased interaction between the HIFα-C-TAD and CBP/p300. Moreover, it was shown that the MEK1 inhibitor PD98059 affected the transactivity of CBP/p300 and that ERK1 could also phosphorylate the transactivation domain of p300 (aa 1751--2414) which subsequently facilitated interaction between the HIF-1α C-TAD and p300 (Sang et al., [@B130]). Together with the finding that phosphorylated HIF-1α is the major form binding to ARNT (Suzuki et al., [@B145]), it appears plausible that HIF-1 transcriptional activity increases in response to induction of the MAPK pathway.

All together, these reports indicate that direct phosphorylation of HIF-1α and HIF-2α by ERK1/2 can affect their nuclear localization and transactivity.

### Links between hypoxia and kinases in the regulation of HIF-1α transactivity

A number of findings have indicated that ERK1/2 can also serve as additional transmitter of the hypoxic signal since hypoxia has been shown to moderately activate ERK1/2 in different cell lines (Salceda et al., [@B129]; Conrad et al., [@B23]; Minet et al., [@B108]). Thereby cell type specific variations may appear as shown for HMEC-1 cells where involvement of ERK1 but not ERK2 in hypoxia-mediated HIF-1 transactivation was reported (Minet et al., [@B108]). In addition, by using PD98059 and by employing a mammalian two-hybrid assay, it was shown that the ERK pathway is also involved in hypoxia-dependent HIF-1α transactivation (Lee et al., [@B91]; Sang et al., [@B130]). By contrast, ERK1/2 activity was not increased in hypoxic growth-arrested Chinese hamster fibroblast CCL39 cells (Richard et al., [@B123]) implying that an activation of either ERK1 or ERK2 in response to hypoxia as well as their involvement in HIFα regulation may be cell type specific. Accordingly, the MEK1 inhibitor PD98059 suppressed hypoxia-mediated HIF-1α transcriptional activity in Hep3B and HMEC-1 cells (Salceda et al., [@B129]; Minet et al., [@B108]) whereas the same inhibitor was ineffective in fibroblasts exposed to hypoxia (Agani and Semenza, [@B1]). However, in all these studies direct mapping of the involved residues within HIFα proteins were not performed; thus only an approximate localization can be given (Figure [4](#F4){ref-type="fig"}).

![**Kinases involved in regulating HIF-1α transactivity**. Scheme of HIF-1α and its domains in which phosphorylation has been shown to affect transactivity. P, represents a phosphorylated amino acid, no specific single residues sites have been mapped. ERK1/2, extracellular regulated kinase1/2; bHLH, basic helix loop helix domain; NLS, nuclear localization sequence; PAS, Per-ARNT-Sim domain; N-TAD, N-terminal transactivation domain; ID, inhibitory domain; C-TAD, C-terminal transactivation domain; numbers indicate the amino acid residue range of the respective domain.](fcell-04-00011-g0004){#F4}

In addition to ERK1/2, protein kinase CK2 (formerly known as casein kinase II) has important functions in the regulation of various cellular processes (Niefind et al., [@B118]; St-Denis and Litchfield, [@B143]; Montenarh, [@B109]). CK2 was shown to affect HIF-1α transcriptional activity (Mottet et al., [@B113]; Hubert et al., [@B65]); however, the exact mechanisms and CK2 phosphorylation sites in HIF-1α were not determined; likely CK2-mediated HIF-1α phosphorylation prevents recruitment of cofactors like CBP/p300 or stimulates HIF-1α degradation in an indirect manner (see below).

Together, these findings indicate an interrelation between hypoxia, ERK1/2, and CK2 signaling pathways in particular for the regulation of HIF-1α transactivity.

Kinases regulating HIFα abundance in an indirect manner {#s5}
=======================================================

In addition to being a direct substrate for kinases, HIFα appears to be regulated via phosphorylation of HIFα regulating proteins in an indirect manner.

The protein kinase A (PKA) is among the best characterized kinases and was suggested to be involved in HIF-1α phosphorylation under intermittent hypoxia in EAhy926 endothelial cells (Toffoli et al., [@B148]). However, from that study it remained open whether or not HIFα proteins can be direct substrates for that kinase since no functional phosphorylation site(s) was identified yet.

As mentioned above, protein kinase CK2, a constitutive serine/threonine kinase which interestingly shows high CK2 activity in most human cancers can indirectly contribute to HIF-1α degradation. Thereby, CK2 phosphorylates S33, S38, and S43 within VHL. Mutation of the CK2 sites within VHL or inhibition of VHL phosphorylation with CK2 inhibitors increased VHL protein half-life and promoted degradation of HIF-1α (Ampofo et al., [@B2]). At the same time inhibited CK2 could also sequester p53 and reduce the transcriptional activity of p53. Together, this indicates that the indirect action of CK2 on HIF-1α and p53 can contribute to the survival of tumor cells (Figure [5](#F5){ref-type="fig"}).

![**Kinases contributing to HIF-1α regulation in an indirect manner**. In response to various hormones, growth factors, cytokines, oncogenes, and stress phosphorylation events can be initiated which contribute to the regulation of HIF-1α in an indirect manner. These can influence HIF-1α mRNA translation, the interaction with cofactors or components of the protein degradation machinery like HDM2 and VHL. Some kinases may act in both ways, however, the knowledge about the exact mechanisms is limited. See text for more details.](fcell-04-00011-g0005){#F5}

One of the best known kinase pathways affecting HIFα in an indirect manner by regulating HIFα protein synthesis involves the mammalian target of rapamycin (mTOR). The mTOR is a serine/threonine protein kinase \[also known as FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)\] (Brown et al., [@B15]; Moore et al., [@B110]) that apart from cell growth, cell proliferation, cell motility, cell survival, and transcription contributes to the regulation of protein synthesis in response to nutrients, hormones, growth factors, cytokines, and stress (for review see Hay and Sonenberg, [@B57]; Beevers et al., [@B10]; Dunlop and Tee, [@B35]). Thereby mTOR regulates translation primarily via phosphorylation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal S6 kinase (S6K) (reviewed by Hay and Sonenberg, [@B57]; Inoki et al., [@B70]). By binding to translation initiation factor 4E (eIF4E) 4E-BP1 prevents interaction of eIF4E with other members of the translation initiation complex and inhibits ribosomal complex formation at the 5′-cap mRNAs. The phosphorylation of 4E-BP1 by mTOR results in its dissociation from eIF4E and in activation of mRNA translation (reviewed by Hay and Sonenberg, [@B57]; Inoki et al., [@B70]). In addition, phosphorylation of ribosomal S6K promotes translation of mRNAs containing a terminal oligopyrimidine tract (5′TOP) in their 5′-UTR (Figure [5](#F5){ref-type="fig"}).

Two major multiprotein complexes can be distinguished in which mTOR contributes to signaling; (i) the rapamycin-sensitive mTOR complex 1 (mTORC1) and (ii) the rapamycin-insensitive mTOR complex 2 (mTORC2) (Wullschleger et al., [@B159]). Several excellent reviews discussing in detail the composition of the TOR complexes and the impact of the participating proteins for signaling are available (see Hay and Sonenberg, [@B57]; Dunlop and Tee, [@B35]) and therefore we limit ourselves to the issue of HIFα regulation. While mTORC1 appears to be involved in nutrient/energy/redox sensing, mTORC2 seems to be mainly regulated by insulin, growth factors, serum and nutrients (Kim et al., [@B83]; Sarbassov et al., [@B131]; Frias et al., [@B44]).

The participation of mTOR in the regulation of HIF-1α protein translation was first shown in a study with breast cancer cells where stimulation with heregulin and HER2 signaling increased the rate of HIF-1α synthesis in a rapamycin-dependent manner (Laughner et al., [@B90]). Other studies in HUVEC and HeLa cells (Kim et al., [@B84]) supported that view and also showed that not only HIF-1α but also HIF-2α was found to be regulated by mTOR signaling, though HIF-1α expression seems to be regulatable by TORC1 and TORC2 whereas HIF-2α expression is primarily dependent on TORC2 (Toschi et al., [@B150]).

Hypoxia has been reported to inhibit mTOR (Arsham et al., [@B5]) via induction of the hypoxia-responsive gene DDIT4 (Dig2/RTP801/REDD1) and subsequent formation of a complex consisting of the tuberous sclerosis tumor suppressor proteins TSC1 (hamartin) and TSC2 (tuberin) (Brugarolas et al., [@B16]). The TSC1/TSC2 complex inhibits primarily mTORC1 signaling; destruction/inhibition of the TSC1/2 complex due to growth factors leads to activation of mTORC1 signaling (Hay and Sonenberg, [@B57]). For removal of TSC2 different kinase pathways, including PI3K/AKT, and ERK1/2 appear to be important (Hay and Sonenberg, [@B57]). Once phosphorylated, TSC2 can be captured by 14-3-3 proteins, thus leaving the complex with TSC1 and rendering mTORC1 active (Li et al., [@B94]).

Reciprocally, the hypoxia mediated inhibition of mTORC1 signaling (Brugarolas et al., [@B16]) appeared to be the result of a dissociation of TSC2 from the growth factor stimulated TSC2/14-3-3 complex. Thereby, hypoxic induction of DDIT4 seemed to be critical. Due to the ability of DDIT4 to bind 14-3-3 proteins this resulted in a release of TSC2 with formation of TSC1/2 complexes which subsequently inhibited of mTORC1 (DeYoung et al., [@B30]).

Thus, DDIT4 and TSC1/TSC2 formation could decrease mTOR activity and would reduce HIF-1α translation under hypoxia. However, under hypoxia when the cellular protein translation is generally suppressed, HIF-1α is still translated. This occurs likely by a mechanism involving the 5′-UTR of the HIF-1α mRNA which contains a terminal oligopyrimidine tract that enables HIF-1α translation even when mTOR is inhibited (Laughner et al., [@B90]; Thomas et al., [@B146]). Like with mTOR, ATR (for ataxia telangiectasia and Rad3 related kinase) appeared also to regulate HIF-1α translation in a region located within the HIF-1α ORF (Fallone et al., [@B39]).

The involvement of mTOR in HIF-1α translation was challenged in studies showing that rapamycin decreased hypoxia-induced HIF-1α stability at the ODD in PC-3 cells (Hudson et al., [@B66]; Dayan et al., [@B27]). Further, mTORC1 appeared to act also directly on HIF-1α since an mTOR signaling motif (FVMVL) modulating recruitment of CBP/p300 was found immediately C-terminal of the PAS-A domain in HIF-1α (Land and Tee, [@B88]). Thus, although mTOR signaling appears to affect HIFα abundance in a more indirect manner, it appears that also direct interactions are possible which may depend on the stimulus.

Growth factor stimulation and hence kinase signaling is not only important for mTOR signaling but also for crosstalk between the HIF-1α and the p53 network (Fukuda et al., [@B45]; Bardos et al., [@B8]). The murine double minute-2 (mdm2) and its human ortholog HDM2 protein are negative regulators of the p53 tumor suppressor protein (for review see Eischen and Lozano, [@B36]; Kruiswijk et al., [@B86]). In addition to p53, HDM2, which is a direct target of PKB/Akt (Ashcroft et al., [@B6]), was shown to regulate HIF-1α expression in response to IGF-1 in p53-null mouse embryo fibroblasts (p53^−∕−^ MEFs) (Bardos et al., [@B8]). Moreover, this appeared to involve protein synthesis and HDM2 phosphorylation at S166 by PKB/Akt (Bardos et al., [@B8]) suggesting that the PKB/Akt pathway also affects HIF-1α synthesis via HDM2 in a p53 independent manner (Figure [5](#F5){ref-type="fig"}).

Altogether, kinases regulating HIFα synthesis or degradation by acting on critical regulators of these processes are important mediators which interlink growth factor controlled pathways with hypoxia signaling.

Exploiting kinases as upstream regulators of HIF-1α in cancer therapy {#s6}
=====================================================================

An impaired regulation of kinase signaling is associated with a number of systemic diseases including cardiovascular diseases, pulmonary diseases, Alzheimer\'s disease, type 2 diabetes mellitus, and last but not least cancer. In particular, intermittent hypoxia in pre-malignant lesions and HIF-1α were proposed to contribute to the reprogramming of metabolism toward permanent conversion of glucose to lactate even in aerobic conditions (Gatenby and Gillies, [@B47]) known as the "Warburg effect," mitochondrial suppression as well as to acidosis. This provides a growth advantage, and an altered response to growth factors which are major actors on kinase signaling pathways. Thus, the interconnection of kinase signaling pathways and hypoxia signaling, i.e., HIFα regulation, is of high therapeutic interest. This is most obvious in cancer therapy where different kinase inhibitors are in clinical use and where severe hypoxic tumors are more resistant to chemotherapy and radiation. Interestingly the most successful kinase inhibitors currently used in cancer therapy are tyrosine kinase inhibitors like imatinib, gefitinib, and erlotinib. Tyrosine kinases are often found to act as receptors for hormones and growth factors and therefore they appear often to have an effect also on HIF-1α which is either direct or indirect (Figure [5](#F5){ref-type="fig"}). In addition to the tyrosine kinase inhibitors, other small molecules with the potential to act on MAPK, mTOR, or Akt pathways are under heavy investigation. Interestingly, the inhibitor of pyruvate dehydrogenase kinase II, dichloroacetate, has been shown to reactivate mitochondria via inhibition of HIF1α involving a PHD-dependent mechanism and a PHD-independent mechanism, involving activation of p53 and GSK3β (Sutendra et al., [@B144]).

However, these inhibitors are often not entirely specific but rather selective which explains their variety of actions as well as their effectiveness also in other disorders, including immunological, neurological, metabolic, and infectious diseases. Although this is already an advantage, it is difficult to predict to which extent kinase inhibitors could be made selective or even specific to target the HIF pathway. This is not only complicated by the fact that the respective kinase having a dominant role in HIFα regulation needs to have a role in the particular tumor entity. Thus, significant challenges remain. In addition to quick evolvement of tumors resistant to kinases inhibitors, appropriate multi-targeted inhibitors or combinations appear currently to be of advance in clinical therapy. Further, more understanding of the kinase inhibitor specificities toward HIF-1α, metabolic and toxic side effects would be needed to optimize cancer therapy.

Conclusion {#s7}
==========

Detailed knowledge about the kinase pathways and their effect on HIFα regulation is essential to optimize and to develop highly efficient cancer therapies. It is now especially necessary to gather more knowledge about the involvement of kinase pathways for the regulation of HIF-2α and HIF-3α since most of the data so far, with respect to kinases and HIFα regulation, have been gained from studies on HIF-1α. Given that certain aspects between HIF-1α and HIF-2α as well as the occurrence of several splice variants of HIF-3α point to more different roles of each HIFα protein in a number of processes, it is obvious that this knowledge would be beneficial for therapeutic purposes.

Overall, the HIFα system appears to be a central integrator of various signals coming from different pathways. Thereby it displays an enormous plasticity being regulated by a number of post-translational modifications, among them phosphorylation, either alone or in combination.
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